Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.

Dr. Greg Riely from MSKCC provides an introduction to the epidermal growth factor receptor (EGFR), what an EGFR mutation means, and which patients are more likely to have them.

Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.

Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering explains how small cell lung cancer and non-small cell lung cancer are differentiated. February 2014.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.

[powerpress]